Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 7/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.53 |
| ▸ | PTGDR2 | Q9Y5Y4 | 12/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31107122 | 1.00 | TMEM97 (0.53) | TMEM97SIGMAR1PTGDR2MEN1ALDH1A1 | |
| SCHEMBL31107140 | 0.86 | TMEM97 (0.53) | TMEM97SIGMAR1PTGDR2 | |
| SCHEMBL25411807 | 0.86 | TMEM97 (0.53) | TMEM97SIGMAR1PTGDR2 | |
| SCHEMBL29554819 | 0.85 | TMEM97 (0.58) | TMEM97SIGMAR1PTGDR2MEN1ALDH1A1 | |
| SCHEMBL30031492 | 0.83 | PTGDR2 (0.63) | PTGDR2 | |
| SCHEMBL15056760 | 0.83 | PTGDR2 (0.66) | PTGDR2 | |
| SCHEMBL15056959 | 0.83 | PTGDR2 (0.63) | PTGDR2 | |
| SCHEMBL25414367 | 0.83 | TMEM97 (0.52) | TMEM97SIGMAR1PTGDR2 | |
| SCHEMBL28097001 | 0.82 | PTGDR2 (0.60) | TMEM97SIGMAR1PTGDR2 | |
| SCHEMBL25412628 | 0.80 | TMEM97 (0.49) | TMEM97SIGMAR1PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250170126-A1 | NOVEL B0AT1 INHIBITOR | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2025-05-29 | — | — | US | disclosed |
| EP-4470533-A1 | NOVEL B0AT1 INHIBITOR | Mitsubishi Tanabe Pharma Corporation (JP) | 2024-12-04 | — | — | EP | disclosed |
| CN-118678949-A | Novel B0AT1 inhibitors | 田边三菱制药株式会社 | 2024-09-20 | — | — | CN | disclosed |
| WO-2023145804-A1 | NOVEL B0AT1 INHIBITOR | 田辺三菱製薬株式会社 | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250170126-A1 | NOVEL B0AT1 INHIBITOR | BCAT1, BCAT2, BHMT | TMEM97 1955/4885SIGMAR1 3072/4885PTGDR2 4694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.